A review of time courses and predictors of lipid changes with fenofibric acid-statin combination
Cardiovascular Drugs and Therapy, 05/30/2012
Filippatos TD – The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high–risk populations, although trials examining cardiovascular disease events are missing.
- Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high–density lipoprotein cholesterol, and low density lipoprotein subspecies.
- Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low– or moderate–dose statin.
- The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose.
- The long–term efficacy of FA combined with low– or moderate– dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects.